Sepsis in South Africa: A Persistent ICU Crisis Demanding Better Antibiotic Strategies

Sepsis remains one of the leading causes of death in intensive care units (ICUs) worldwide, and South Africa faces an acutely high burden. In urban African settings like Johannesburg, population incidence rates for adult sepsis can reach 1772 per 100,000, with severe cases at 303 per 100,000. One in three ICU admissions in South African hospitals meets the Sepsis-3 criteria, exacerbated by high rates of nosocomial infections, HIV prevalence, and antimicrobial resistance (AMR). At facilities like Chris Hani Baragwanath Academic Hospital, affiliated with the University of the Witwatersrand (Wits), clinicians grapple with resource constraints including power outages, limited staffing, and a pathogen profile where over 60% exhibit resistance profiles ranging from extended-spectrum beta-lactamase (ESBL) producers to pan-drug resistant strains.

This context underscores the urgency for optimized antibiotic therapy. Beta-lactam antibiotics—such as penicillins, cephalosporins, carbapenems, and monobactams (e.g., piperacillin-tazobactam, meropenem)—form the backbone of empirical sepsis treatment due to their broad-spectrum activity against Gram-positive, Gram-negative, and anaerobic bacteria. However, their time-dependent bactericidal mechanism, reliant on the percentage of time the free drug concentration exceeds the minimum inhibitory concentration (fT>MIC), challenges standard intermittent bolus (IB) dosing in critically ill patients.

Check out higher education jobs in South Africa for opportunities in clinical research at institutions like Wits.

Pharmacodynamics of Beta-Lactams: Why Continuous Infusion Sparks Debate

Beta-lactams inhibit bacterial cell wall synthesis by binding penicillin-binding proteins, a process most effective when drug levels remain above the pathogen's MIC for 40-100% of the dosing interval, depending on the agent and site of infection. In stable patients, IB every 6-8 hours suffices, but sepsis induces pathophysiological changes: augmented renal clearance (ARC), expanded volume of distribution from capillary leak, and hypoalbuminemia reduce peak concentrations and shorten half-life, often yielding subtherapeutic levels with IB.

Continuous infusion (CI) delivers steady-state concentrations, theoretically maximizing fT>MIC without excessive peaks that risk toxicity. Preclinical and early PK/PD studies support CI, but clinical translation varies. Meta-analyses of prolonged infusions (3-24 hours) show reduced mortality (RR 0.84) and higher clinical cure in sepsis. Yet, large RCTs like BLING III (7,031 patients) found no 90-day mortality benefit (RR 0.95) despite improved clinical cure.

• Advantages of CI: Optimal PK/PD target attainment (e.g., 100% fT>MIC), reduced resistance selection pressure.
• Challenges: Requires infusion pumps, stability data, clinician training.

In resource-limited ICUs, IB remains default, prompting Wits researchers to test CI locally.

Wits University Launches Landmark RCT on Beta-Lactam Dosing

Led by Division of Critical Care at Wits and Chris Hani Baragwanath Academic Hospital, this prospective, open-label RCT (November 2020-February 2023) randomized 122 adults (≥18 years) with Sepsis-3 to CI or IB of four beta-lactams: amoxicillin-clavulanate, piperacillin-tazobactam, imipenem-cilastatin, or meropenem. First such trial in a lower-middle-income country (LMIC) ICU with high AMR.

Exclusion criteria ensured relevance: no prior >24h study drug, no pregnancy, no renal replacement therapy, no allergy. Stratified randomization (1:1) by antibiotic used permuted blocks, concealed via sealed envelopes. Dosing per clinician judgment; CI included loading dose if needed. Intention-to-treat analysis powered for 11% clinical cure increase (target 290 patients, underpowered at 122 due to COVID disruptions).

Baseline balanced: median age 44, APACHE II 23, SOFA 7, 40% HIV-positive, common sites pneumonia (45%), intra-abdominal (20%). Pathogens (52 culture-positive): 60.2% resistant (31.4% ESBL, 13.7% pan-resistant).

Results: Trends Favor CI but No Statistical Superiority

Primary outcome—day 14 clinical cure (antibiotic completion without restart <48h)—81.3% CI (52/64) vs 74.1% IB (43/58), RR 1.10 (0.91-1.33), p=0.345. Absolute 7.2% difference trended positive.

Secondary: Day 90 mortality RR 0.57 (95% CI 0.32-1.01, p=0.056)—borderline, favoring CI. No differences in ICU length-of-stay (9.5 vs 9 days), ventilation/vasopressor/renal support duration. No adverse events halted therapy.

Subgroup by antibiotic showed consistency. Serum levels monitored in subset confirmed adequate exposure.

High AMR Context Amplifies Study Relevance in South Africa

South Africa's ICUs battle ESBL (common in Klebsiella, E. coli), carbapenem-resistant Enterobacterales, and Acinetobacter extremes. Study pathogens reflected this: 60.2% resistant, higher than many high-income settings. CI may counter by maximizing exposure, potentially delaying resistance emergence despite no PK data here (prior Wits PK studies show ARC in 50% sepsis patients).

In LMICs, sepsis mortality exceeds 40%; optimized dosing could save lives amid limited new antibiotics. Wits' open ICU model (no negative pressure) heightens nosocomial risk, making stewardship vital.

Global Comparisons: Aligning with BLING III and Meta-Analyses

BLING III (Australia/New Zealand, 7,031 sepsis patients) mirrored trends: no mortality benefit (55.8% CI vs 55.3% IB) but higher cure (64.6% vs 59.0%). Wits' smaller scale echoes this, with stronger mortality signal possibly from higher-risk cohort/resistance.

Meta-analysis (9,166 patients): prolonged infusion cuts ICU mortality (RR 0.84). Cumulative evidence tilts toward CI/prolonged for clinical cure, especially resistant infections.

• BLING III: Powered for mortality, found PK/PD benefit.
• Wits: LMIC-first, high AMR, feasibility proof.
• Meta: Supports adoption in sepsis guidelines.

PK/PD Nuances in Critically Ill: Augmented Clearance and Hypoalbuminemia

Sepsis alters beta-lactam PK: glomerular hyperfiltration (CrCl >130 ml/min in ARC) halves half-life; fluid resuscitation expands Vd 2-3x. IB peaks high but troughs low (<MIC 50% time); CI achieves 100% fT>MIC at steady-state (3-4 half-lives post-load).

Wits prior work: Piperacillin/meropenem subtherapeutic in 25-50% bolus-dosed sepsis patients. CI counters this, but needs pumps (cost ~R5000, lifespan shortened by loadshedding).

LMIC Barriers and Implementation Strategies from Wits Experience

Resource hurdles: Infusion devices vulnerable to interruptions; no 24/7 pharmacists for TDM. Wits succeeded via clinician-led dosing, proving feasibility. Strategies:

• Standardized protocols with loading doses.
• Stability validation for 24h bags.
• Training amid nurse shortages.

Cost-benefit: Potential cure gains offset pumps (CI ~R10/day more). AMR stewardship aligns with SA Antibiotic Stewardship Programme.

Explore higher ed career advice for clinical pharmacology roles in South African universities.

Wits' Pivotal Role in Critical Care Research and Higher Education

Wits, Africa's top university, drives sepsis innovation via SAMRC Centre for Excellence, training next-gen intensivists. This trial highlights interdisciplinary collaboration (UQ, Malaysia, France), boosting global visibility. Outputs: Publications, guidelines influence; attracts funding/jobs in South African university jobs.

Impacts higher ed: Builds research capacity, counters brain drain, positions Wits in AMR fight.

Future Outlook: Larger Trials and Precision Dosing

Needed: Powered LMIC RCTs with PK-guided dosing, TDM integration, resistance endpoints. AI models predict ARC; beta-lactamase inhibitors pair well. SA policy: Incorporate CI in sepsis bundles.

Optimism: Trends + meta-data suggest CI niche role, especially high-MIC pathogens.

Key Takeaways and Calls to Action for Clinicians and Researchers

Wits study adds vital LMIC evidence: CI safe, feasible, trends better outcomes in resistant sepsis. Implement judiciously; monitor resistance.

For academics: Join university jobs at Wits. Healthcare pros: Explore higher-ed jobs in research. Share insights on Rate My Professor; career tips at higher ed career advice. Post jobs at post a job.

Photo by National Cancer Institute on Unsplash